Congenital myasthenic syndromes

Kinji Ohno, Andrew G Engel

Research output: Contribution to journalArticle

Abstract

Congenital myasthenic syndromes (CMS) are caused by genetic defects of molecules expressed at the neuromuscular junction. Mutations identified to date include (1) MuSK, a receptor for neural agrin that plays a pivotal role in formation of the neuromuscular junction, (2) choline acetyltransferase that resynthesizes acetylcholine at the nerve terminal, (3) collagen Q that anchors acetylcholinesterase at the synaptic basal lamina, (4) rapsyn that clusters acetylcholine receptor (AChR) at the endplate, (5) AChR subunits, and (6) skeletal muscle voltage-gated sodium channel (Na v1.4). Mutations in the AChR subunit genes cause slow-channel syndrome in which channel opening events are prolonged, fast-channel syndrome that is characterized by short channel opening events, and/or endplate AChR deficiency. Slow channel syndrome is an autosomal dominant disorder, whereas the others are all caused by autosomal recessive mutations. Adult-onset cases of CMS are most commonly observed in slow channel syndrome, but are also observed in other types of CMS. CMS are frequently associated with muscle atrophy, and/or mild orofacial anomalies. CMS should be considered in diagnosing not only myasthenia gravis but also other types of myopathies. Low- and high-frequency repetitive nerve stimulations to any patient that exhibits muscle weakness are highly recommended for diagnosing CMS.

Original languageEnglish (US)
Pages (from-to)326-335
Number of pages10
JournalNeuro-Ophthalmology Japan
Volume22
Issue number3
StatePublished - 2005

Fingerprint

Congenital Myasthenic Syndromes
Cholinergic Receptors
Neuromuscular Junction
Mutation
Voltage-Gated Sodium Channels
Choline O-Acetyltransferase
Muscular Atrophy
Myasthenia Gravis
Muscle Weakness
Sensory Receptor Cells
Muscular Diseases
Acetylcholinesterase
Basement Membrane
Acetylcholine
Skeletal Muscle
Collagen

Keywords

  • Congenital myasthenic syndromes
  • Myasthenia gravis
  • Neuromuscular junction
  • Neuromuscular transmission

ASJC Scopus subject areas

  • Ophthalmology
  • Clinical Neurology

Cite this

Congenital myasthenic syndromes. / Ohno, Kinji; Engel, Andrew G.

In: Neuro-Ophthalmology Japan, Vol. 22, No. 3, 2005, p. 326-335.

Research output: Contribution to journalArticle

Ohno, K & Engel, AG 2005, 'Congenital myasthenic syndromes', Neuro-Ophthalmology Japan, vol. 22, no. 3, pp. 326-335.
Ohno, Kinji ; Engel, Andrew G. / Congenital myasthenic syndromes. In: Neuro-Ophthalmology Japan. 2005 ; Vol. 22, No. 3. pp. 326-335.
@article{ff291ed7da8149d0983f8f6763bf0177,
title = "Congenital myasthenic syndromes",
abstract = "Congenital myasthenic syndromes (CMS) are caused by genetic defects of molecules expressed at the neuromuscular junction. Mutations identified to date include (1) MuSK, a receptor for neural agrin that plays a pivotal role in formation of the neuromuscular junction, (2) choline acetyltransferase that resynthesizes acetylcholine at the nerve terminal, (3) collagen Q that anchors acetylcholinesterase at the synaptic basal lamina, (4) rapsyn that clusters acetylcholine receptor (AChR) at the endplate, (5) AChR subunits, and (6) skeletal muscle voltage-gated sodium channel (Na v1.4). Mutations in the AChR subunit genes cause slow-channel syndrome in which channel opening events are prolonged, fast-channel syndrome that is characterized by short channel opening events, and/or endplate AChR deficiency. Slow channel syndrome is an autosomal dominant disorder, whereas the others are all caused by autosomal recessive mutations. Adult-onset cases of CMS are most commonly observed in slow channel syndrome, but are also observed in other types of CMS. CMS are frequently associated with muscle atrophy, and/or mild orofacial anomalies. CMS should be considered in diagnosing not only myasthenia gravis but also other types of myopathies. Low- and high-frequency repetitive nerve stimulations to any patient that exhibits muscle weakness are highly recommended for diagnosing CMS.",
keywords = "Congenital myasthenic syndromes, Myasthenia gravis, Neuromuscular junction, Neuromuscular transmission",
author = "Kinji Ohno and Engel, {Andrew G}",
year = "2005",
language = "English (US)",
volume = "22",
pages = "326--335",
journal = "Neuro-Ophthalmology Japan",
issn = "0289-7024",
publisher = "Neuro-Ophthalmology Society of Japan",
number = "3",

}

TY - JOUR

T1 - Congenital myasthenic syndromes

AU - Ohno, Kinji

AU - Engel, Andrew G

PY - 2005

Y1 - 2005

N2 - Congenital myasthenic syndromes (CMS) are caused by genetic defects of molecules expressed at the neuromuscular junction. Mutations identified to date include (1) MuSK, a receptor for neural agrin that plays a pivotal role in formation of the neuromuscular junction, (2) choline acetyltransferase that resynthesizes acetylcholine at the nerve terminal, (3) collagen Q that anchors acetylcholinesterase at the synaptic basal lamina, (4) rapsyn that clusters acetylcholine receptor (AChR) at the endplate, (5) AChR subunits, and (6) skeletal muscle voltage-gated sodium channel (Na v1.4). Mutations in the AChR subunit genes cause slow-channel syndrome in which channel opening events are prolonged, fast-channel syndrome that is characterized by short channel opening events, and/or endplate AChR deficiency. Slow channel syndrome is an autosomal dominant disorder, whereas the others are all caused by autosomal recessive mutations. Adult-onset cases of CMS are most commonly observed in slow channel syndrome, but are also observed in other types of CMS. CMS are frequently associated with muscle atrophy, and/or mild orofacial anomalies. CMS should be considered in diagnosing not only myasthenia gravis but also other types of myopathies. Low- and high-frequency repetitive nerve stimulations to any patient that exhibits muscle weakness are highly recommended for diagnosing CMS.

AB - Congenital myasthenic syndromes (CMS) are caused by genetic defects of molecules expressed at the neuromuscular junction. Mutations identified to date include (1) MuSK, a receptor for neural agrin that plays a pivotal role in formation of the neuromuscular junction, (2) choline acetyltransferase that resynthesizes acetylcholine at the nerve terminal, (3) collagen Q that anchors acetylcholinesterase at the synaptic basal lamina, (4) rapsyn that clusters acetylcholine receptor (AChR) at the endplate, (5) AChR subunits, and (6) skeletal muscle voltage-gated sodium channel (Na v1.4). Mutations in the AChR subunit genes cause slow-channel syndrome in which channel opening events are prolonged, fast-channel syndrome that is characterized by short channel opening events, and/or endplate AChR deficiency. Slow channel syndrome is an autosomal dominant disorder, whereas the others are all caused by autosomal recessive mutations. Adult-onset cases of CMS are most commonly observed in slow channel syndrome, but are also observed in other types of CMS. CMS are frequently associated with muscle atrophy, and/or mild orofacial anomalies. CMS should be considered in diagnosing not only myasthenia gravis but also other types of myopathies. Low- and high-frequency repetitive nerve stimulations to any patient that exhibits muscle weakness are highly recommended for diagnosing CMS.

KW - Congenital myasthenic syndromes

KW - Myasthenia gravis

KW - Neuromuscular junction

KW - Neuromuscular transmission

UR - http://www.scopus.com/inward/record.url?scp=27744497503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744497503&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:27744497503

VL - 22

SP - 326

EP - 335

JO - Neuro-Ophthalmology Japan

JF - Neuro-Ophthalmology Japan

SN - 0289-7024

IS - 3

ER -